Construction of Molecular Diagnostic Marker Model for Pancreatic Cystic Tumors Based on Pancreatic Cystic Fluid Samples

Launched by ZHAOSHEN LI · Feb 17, 2023

Keywords

ClinConnect Summary

This clinical trial is studying pancreatic cystic tumors, which are fluid-filled growths in the pancreas. The main goal is to find specific markers in the fluid from these tumors that can help doctors tell whether a tumor is benign (non-cancerous) or malignant (cancerous). Researchers will analyze the genetic material and proteins in the cyst fluid to better understand the tumors and their characteristics, which could lead to improved diagnosis and treatment.

To participate, individuals need to be at least 18 years old and have been diagnosed with a pancreatic cyst that may require surgery. They should be willing to undergo surgery to remove the cyst and provide a sample of the cyst fluid afterward. Those who have had certain treatments or medications before the surgery, or who do not want to participate, will not be eligible. Participants can expect to contribute to important research that may help improve understanding and management of pancreatic cystic tumors.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Subjects are ≥ 18 years old, regardless of gender;
• • Preoperative imaging examination (EUS, CT, MRI) diagnosed cystic mass of pancreas and suspected cystic tumor;
• • Subjects voluntarily accepted radical resection of pancreatic cystic tumors;
• • Subjects or family members voluntarily sign the informed consent form for clinical research.
• Exclusion Criteria:
• • The excised sample does not contain cystic components, or the cystic fluid cannot be collected;
• • Receive tumor-related treatment (radiotherapy, chemotherapy, immunotherapy, etc.) before operation;
• • Receive antibiotic treatment within 1 week before operation;
• • Subjects refused to accept radical resection of pancreatic cystic tumor, or had any situation that they could not accept radical resection of pancreatic cystic tumor;
• • The subjects or their families refused to sign the informed consent form for clinical research.